

VU Research Portal

The genetics of Early Onset Parkinsonism

Macedo, M.

2012

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Macedo, M. (2012). *The genetics of Early Onset Parkinsonism*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

REFERENCES

REFERENCES

- Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R and others. 1999. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. *Hum Mol Genet* 8(4):567-74.
- Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A and others. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. *Neuron* 25(1):239-52.
- Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. 2003. The role of pathogenic DJ-1 mutations in Parkinson's disease. *Ann Neurol* 54(3):283-6.
- Aebersold R, Mann M. 2003. Mass spectrometry-based proteomics. *Nature* 422(6928):198-207.
- Affymetrix. 2006. BRLMM: an improved genotype calling method for the GeneChip Human Mapping 500K Array Set. Technical Report, White Paper (Affymetrix, Inc, Santa Clara, CA).
- Ahlborn E, Prins GS, Ceccatelli S. 2001. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. *Brain Res* 892(2):255-62.
- Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, Kim YK, Kim SE, Kim JM, Kim HJ and others. 2008. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. *Neurology* 70(1):43-9.
- Auluck PK, Caraveo G, Lindquist S. 2010. alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. *Annu Rev Cell Dev Biol* 26:211-33.
- Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, Reid JG, Fink JK, Morgan MB, Gingras MC and others. 2011. Whole-genome sequencing for optimized patient management. *Sci Transl Med* 3(87):87re3.
- Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW and others. 2004. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. *Brain* 127(Pt 2):420-30.

- Bandyopadhyay S, Cookson MR. 2004. Evolutionary and functional relationships within the DJ1 superfamily. *BMC Evol. Biol.* 4(1):6.
- Banerjee R, Starkov AA, Beal MF, Thomas B. 2009. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. *Biochim Biophys Acta* 1792(7):651-63.
- Bassetti CL. 2011. Nonmotor disturbances in Parkinson's disease. *Neurodegener Dis* 8(3):95-108.
- Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, Negro A, Forloni G. 2008. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. *PLoS One* 3(4):e1884.
- Baulac S, LaVoie MJ, Strahle J, Schlossmacher MG, Xia W. 2004. Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain. *Mol Cell Neurosci* 27(3):236-46.
- Benito-Leon J. 2009. How common is essential tremor? *Neuroepidemiology* 32(3):215-6.
- Benmoyal-Segal L, Soreq H. 2006. Gene-environment interactions in sporadic Parkinson's disease. *J Neurochem* 97(6):1740-55.
- Berg D, Niwar M, Maass S, Zimprich A, Moller J. C, Wuellner U, Schmitz-Hubsch T, Klein C, Tan E. K, Schols L and others. 2005. Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients. *Mov Disord.* 20(9):1191-4.
- Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. *Nat Rev Mol Cell Biol* 8(12):1006-16.
- Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, Martignoni E, Lopiano L, Lamberti P, Fincati E and others. 2005. Novel parkin mutations detected in patients with early-onset Parkinson's disease. *Mov Disord* 20(4):424-31.
- Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. 2002. Glutathione, iron and Parkinson's disease. *Biochem Pharmacol* 64(5-6):1037-48.
- Bisaglia M, Mammi S, Bubacco L. 2009. Structural insights on physiological functions and pathological effects of alpha-synuclein. *Faseb J* 23(2):329-40.
- Blackinton J, Ahmad R, Miller DW, van der Brug MP, Canet-Aviles RM, Hague SM, Kaleem M, Cookson MR. 2005. Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. *Brain Res Mol Brain Res* 134(1):76-83.
- Bodmer W, Bonilla C. 2008. Common and rare variants in multifactorial susceptibility to common diseases. *Nat Genet* 40(6):695-701.
- Bogaerts V, Nuytemans K, Reumers J, Pals P, Engelborghs S, Pickut B, Corsmit E, Peeters K, Schymkowitz J, De Deyn PP and others. 2008. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. *Hum Mutat* 29(6):832-40.

- Bonifati V. 2009. Is GIGYF2 the defective gene at the PARK11 locus? *Curr Neurol Neurosci Rep* 9(3):185-7.
- Bonifati V, Oostra BA, Heutink P. 2004a. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. *J Mol Med* 82(3):163-74.
- Bonifati V, Oostra BA, Heutink P. 2004b. Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms. *Cell Mol Life Sci* 61(14):1729-50.
- Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M and others. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 299(5604):256-9.
- Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR, Cunha L, Hardy J, Singleton A. 2005. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. *Mov Disord* 20(12):1653-5.
- Breen DP, Rowe JB, Barker RA. 2011. Role of brain imaging in early parkinsonism. *BMJ* 342:d638.
- Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P and others. 2011. Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues. *Arch Neurol*.
- Bross P, Corydon TJ, Andresen BS, Jorgensen MM, Bolund L, Gregersen N. 1999. Protein misfolding and degradation in genetic diseases. *Hum Mutat* 14(3):186-98.
- Burrows JF, McGrattan MJ, Rascole A, Humbert M, Baek KH, Johnston JA. 2004. DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. *J Biol Chem* 279(14):13993-4000.
- Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. 2004. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. *Proc Natl Acad Sci U S A* 101(24):9103-8.
- Cazeneuve C, San C, Ibrahim SA, Mukhtar MM, Kheir MM, Leguern E, Brice A, Salih MA. 2009. A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson's disease. *Neurogenetics* 10(3):265-70.
- Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M and others. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet* 364(9440):1167-9.
- Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. 2006. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. *Mov Disord* 21(7):1002-7.

- Chen J, Li L, Chin LS. 2010. Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. *Hum Mol Genet* 19(12):2395-408.
- Chi KR. 2009. Human genetics: Hit or miss? *Nature* 461(7265):712-4.
- Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. 2001. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. *Nat Med* 7(10):1144-50.
- Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. 2006. *Drosophila* pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature* 441(7097):1162-6.
- Clark LN, Afridi S, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Singleton A, Wavrant De-Vrieze F, Hardy J and others. 2004. Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. *Mov Disord* 19(7):796-800.
- Consortium IPDG. 2011. A two-stage meta-analysis identifies several new loci for Parkinson's disease. *PLoS Genet* 7(6):e1002142.
- Cook C, Petrucelli L. 2009. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. *Biochim Biophys Acta* 1792(7):664-75.
- Cookson MR. 2003a. Parkin's substrates and the pathways leading to neuronal damage. *Neuromolecular Med* 3(1):1-13.
- Cookson MR. 2003b. Pathways to Parkinsonism. *Neuron* 37(1):7-10.
- Cookson MR. 2005. The biochemistry of Parkinson's disease. *Annu Rev Biochem* 74:29-52.
- Cookson MR, Lockhart PJ, McLendon C, O'Farrell C, Schlossmacher M, Farrer MJ. 2003. RING finger 1 mutations in Parkin produce altered localization of the protein. *Hum Mol Genet* 12(22):2957-65.
- Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F and others. 2006. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science* 313(5785):324-8.
- Crosiers D, Theuns J, Cras P, Van Broeckhoven C. 2011. Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. *J Chem Neuroanat* 42(2):131-41.
- Dachsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V and others. 2006. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. *Neurosci Lett* 410(2):80-4.
- Darios F, Ruiperez V, Lopez I, Villanueva J, Gutierrez LM, Davletov B. 2010. Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. *EMBO Rep* 11(7):528-33.

- Das SK, Misra AK, Ray BK, Hazra A, Ghosal MK, Chaudhuri A, Roy T, Banerjee TK, Raut DK. 2010. Epidemiology of Parkinson disease in the city of Kolkata, India: A community-based study. *Neurology* 75(15):1362-9.
- Dauer W, Ho CC. 2010. The biology and pathology of the familial Parkinson's disease protein LRRK2. *Mov Disord* 25 Suppl 1:S40-3.
- Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. *Neuron* 39(6):889-909.
- Davidson WS, Jonas A, Clayton DF, George JM. 1998. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. *J Biol Chem* 273(16):9443-9.
- Dawson TM, Dawson VL. 2003. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. *J Clin Invest* 111(2):145-51.
- de Lau LM, Breteler MM. 2006. Epidemiology of Parkinson's disease. *Lancet Neurol* 5(6):525-35.
- De Palma G, Mozzoni P, Mutti A, Calzetti S, Negrotti A. 1998. Case-control study of interactions between genetic and environmental factors in Parkinson's disease. *Lancet* 352(9145):1986-7.
- de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C and others. 2000. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. *Neurologic Diseases in the Elderly Research Group. Neurology* 54(11 Suppl 5):S21-3.
- Dellaire G, Bazett-Jones DP. 2004. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. *Bioessays* 26(9):963-77.
- Denslow SA, Wade PA. 2007. The human Mi-2/NuRD complex and gene regulation. *Oncogene* 26(37):5433-8.
- Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. 2008. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. *J Biol Chem* 283(14):9089-100.
- Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S. 2008. Pesticide/environmental exposures and Parkinson's disease in East Texas. *J Agromedicine* 13(1):37-48.
- Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH and others. 2009. FBOX7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. *Neurology* 72(3):240-5.
- Di Ilio C, Sacchetta P, Iannarelli V, Aceto A. 1995. Binding of pesticides to alpha, mu and pi class glutathione transferase. *Toxicol Lett* 76(2):173-7.

- Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK and others. 2009. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. *Lancet Neurol* 8(12):1150-7.
- Djarmati A, Hedrich K, Svetel M, Schafer N, Juric V, Vukosavic S, Hering R, Riess O, Romac S, Klein C and others. 2004. Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients. *Hum Mutat* 23(5):525.
- Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW and others. 2011. Web-based genome-wide association study identifies two novel Loci and a substantial genetic component for Parkinson's disease. *PLoS Genet* 7(6):e1002141.
- Dodson MW, Guo M. 2007. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. *Curr Opin Neurobiol* 17(3):331-7.
- Dorval V, Fraser PE. 2006. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. *J Biol Chem* 281(15):9919-24.
- Dorval V, Fraser PE. 2007. SUMO on the road to neurodegeneration. *Biochim Biophys Acta* 1773(6):694-706.
- Du X, Choi IG, Kim R, Wang W, Jancarik J, Yokota H, Kim SH. 2000. Crystal structure of an intracellular protease from *Pyrococcus horikoshii* at 2-Å resolution. *Proc Natl Acad Sci U S A* 97(26):14079-84.
- Dyson SC, Barker RA. 2011. Cell-based therapies for Parkinson's disease. *Expert Rev Neurother* 11(6):831-44.
- Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S, Konidari I, Wang G and others. 2010. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. *Ann Hum Genet* 74(2):97-109.
- Edwards TM, Myers JP. 2007. Environmental exposures and gene regulation in disease etiology. *Environ Health Perspect* 115(9):1264-70.
- El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. 2006. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. *FASEB J* 20(3):419-25.
- Elbaz A, Grigoletto F, Baldereschi M, Breteler MM, Manubens-Bertran JM, Lopez-Pousa S, Dartigues JF, Alperovitch A, Tzourio C, Rocca WA. 1999. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EURO-PARKINSON Study Group. *Neurology* 52(9):1876-82.

- Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC and others. 2011. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. *Ann Neurol* 69(5):778-92.
- Falcone DC, Wood EM, Xie SX, Siderowf A, Van Deerlin VM. 2011. Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest. *J Genet Couns* 20(4):384-95.
- Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. 2003. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. *Mov Disord* 18(11):1312-6.
- Fan J, Ren H, Fei E, Jia N, Ying Z, Jiang P, Wu M, Wang G. 2008a. Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. *FEBS Lett* 582(7):1151-6.
- Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P, Wu M, Wang G. 2008b. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. *J Biol Chem* 283(7):4022-30.
- Fang D, Kerppola TK. 2004. Ubiquitin-mediated fluorescence complementation reveals that Jun ubiquitinated by Itch/AIP4 is localized to lysosomes. *Proc Natl Acad Sci U S A* 101(41):14782-7.
- Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J and others. 2001. Lewy bodies and parkinsonism in families with parkin mutations. *Ann Neurol* 50(3):293-300.
- Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D and others. 2004. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. *Ann Neurol* 55(2):174-9.
- Feany MB, Bender WW. 2000. A *Drosophila* model of Parkinson's disease. *Nature* 404(6776):394-8.
- Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. 2011. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. *J Neural Transm* 118(5):821-39.
- Feuk L, Carson AR, Scherer SW. 2006. Structural variation in the human genome. *Nat Rev Genet* 7(2):85-97.
- Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ, Jr., Rothlind J, Sagher O, Moy C and others. 2010. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. *N Engl J Med* 362(22):2077-91.
- Forno LS. 1996. Neuropathology of Parkinson's disease. *J Neuropathol Exp Neurol* 55(3):259-72.
- Fox SH, Chuang R, Brotchie JM. 2009. Serotonin and Parkinson's disease: On movement, mood, and madness. *Mov Disord* 24(9):1255-66.

- Gaig C, Marti MJ, Ezquerro M, Rey MJ, Cardozo A, Tolosa E. 2007. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. *J Neurol Neurosurg Psychiatry* 78(6):626-8.
- Gasser T. 2001. Genetics of Parkinson's disease. *J Neurol* 248(10):833-40.
- Gasser T, Muller-Mysok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznoi B, Fabrizio E, Vieregge P, Horstmann RD. 1998. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. *Nat Genet* 18(3):262-5.
- Geiss-Friedlander R, Melchior F. 2007. Concepts in sumoylation: a decade on. *Nat Rev Mol Cell Biol* 8(12):947-56.
- Giaime E, Sunyach C, Druon C, Scarzello S, Robert G, Grosso S, Auberger P, Goldberg MS, Shen J, Heutink P and others. 2010. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. *Cell Death Differ* 17(1):158-69.
- Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VM. 2000. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. *J Neurosci Res* 59(4):528-33.
- Giasson BI, Lee VM. 2001. Parkin and the molecular pathways of Parkinson's disease. *Neuron* 31(6):885-8.
- Giasson BI, Murray IV, Trojanowski JQ, Lee VM. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. *J Biol Chem* 276(4):2380-6.
- Gibb WR, Lees AJ. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 51(6):745-52.
- Gibson J, Morton NE, Collins A. 2006. Extended tracts of homozygosity in outbred human populations. *Hum Mol Genet* 15(5):789-95.
- Gietz RD, Woods RA. 2002. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. *Methods Enzymol* 350:87-96.
- Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. *Hum Mol Genet* 15(2):223-32.
- Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. 2004. Parkinsonism among Gaucher disease carriers. *J Med Genet* 41(12):937-40.
- Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ and others. 2003. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. *J Biol Chem* 278(44):43628-35.

- Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C and others. 2005. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. *J Med Genet* 42(11):e65.
- Graham FL, van der Eb AJ. 1973. Transformation of rat cells by DNA of human adenovirus 5. *Virology* 54(2):536-9.
- Greenamyre JT, Hastings TG. 2004. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. *Science* 304(5674):1120-2.
- Gregersen N, Bross P, Jorgensen MM, Corydon TJ, Andresen BS. 2000. Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders. *J Inherit Metab Dis* 23(5):441-7.
- Gregersen N, Winter VS, Corydon MJ, Corydon TJ, Rinaldo P, Ribes A, Martinez G, Bennett MJ, Vianey-Saban C, Bhala A and others. 1998. Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: one of the variant alleles, 511C-->T, is present at an unexpectedly high frequency in the general population, as was the case for 625G-->A, together conferring susceptibility to ethylmalonic aciduria. *Hum Mol Genet* 7(4):619-27.
- Greggio E, Bisaglia M, Civiero L, Bubacco L. 2011. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? *Mol Neurodegener* 6(1):6.
- Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ and others. 2006. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiol Dis* 23(2):329-41.
- Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A and others. 2008. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. *J Biol Chem* 283(24):16906-14.
- Hague S, Rogaeva E, Hernandez D, Gulick C, Singleton A, Hanson M, Johnson J, Weiser R, Gallardo M, Ravina B and others. 2003. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. *Ann Neurol* 54(2):271-4.
- Halliday G, Lees A, Stern M. 2011. Milestones in Parkinson's disease--clinical and pathologic features. *Mov Disord* 26(6):1015-21.
- Hamilton RL. 2000. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. *Brain Pathol* 10(3):378-84.

- Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E and others. 2010. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. *Nat Genet* 42(9):781-5.
- Haque ME, Thomas KJ, D'Souza C, Callaghan S, Kitada T, Slack RS, Fraser P, Cookson MR, Tandon A, Park DS. 2008. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. *Proc Natl Acad Sci U S A* 105(5):1716-21.
- Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. 2009. The genetics of Parkinson's syndromes: a critical review. *Curr Opin Genet Dev* 19(3):254-65.
- Hardy J, Singleton A. 2009. Genomewide association studies and human disease. *N Engl J Med* 360(17):1759-68.
- Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, Yoshino H, Asahina M, Kobayashi S, Hassin-Baer S and others. 2004. Novel PINK1 mutations in early-onset parkinsonism. *Ann Neurol* 56(3):424-7.
- Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M and others. 1998. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. *Biochem Biophys Res Commun* 249(3):754-8.
- Hay RT. 2005. SUMO: a history of modification. *Mol Cell* 18(1):1-12.
- Hayashi S, Wakabayashi K, Ishikawa A, Nagai H, Saito M, Maruyama M, Takahashi T, Ozawa T, Tsuji S, Takahashi H. 2000. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. *Mov Disord* 15(5):884-8.
- Hayes JD, Flanagan JU, Jowsey IR. 2005. Glutathione transferases. *Annu Rev Pharmacol Toxicol* 45:51-88.
- Healy DG, Abou-Sleiman PM, Wood NW. 2004. Genetic causes of Parkinson's disease: UCHL-1. *Cell Tissue Res* 318(1):189-94.
- Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S and others. 2008. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol* 7(7):583-90.
- Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, Hilker R, Vieregge P, Ozelius LJ, Heutink P and others. 2004a. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. *Neurology* 62(3):389-94.
- Hedrich K, Eskelson C, Wilmot B, Marder K, Harris J, Garrels J, Meija-Santana H, Vieregge P, Jacobs H, Bressman SB and others. 2004b. Distribution, type, and origin of Parkin mutations: review and case studies. *Mov Disord* 19(10):1146-57.

- Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO and others. 2001. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. *Hum Mol Genet* 10(16):1649-56.
- Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, Pramstaller PP, Schwinger E, Bressman SB, Fahn S and others. 2002. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. *Neurology* 58(8):1239-46.
- Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E, Volkmann J, Pramstaller PP, Kostic V, Vieregge P and others. 2006. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. *Mov Disord* 21(9):1506-10.
- Hely MA, Morris JG, Reid WG, Trafficante R. 2005. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. *Mov Disord* 20(2):190-9.
- Heun P. 2007. SUMO organization of the nucleus. *Curr Opin Cell Biol* 19(3):350-5.
- Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, Frigge ML, Kong A, Gulcher JR, Stefansson K and others. 2002. A susceptibility gene for late-onset idiopathic Parkinson's disease. *Ann Neurol* 52(5):549-55.
- Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, Lenz O, Vieregge P, Herholz K, Heiss WD and others. 2001. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. *Ann Neurol* 49(3):367-76.
- Hisahara S, Shimohama S. 2010. Toxin-induced and genetic animal models of Parkinson's disease. *Parkinsons Dis* 2011:951709.
- Hod Y, Pentiyala SN, Whyard TC, El-Maghrabi MR. 1999. Identification and characterization of a novel protein that regulates RNA-protein interaction. *J Cell Biochem* 72(3):435-44.
- Honbou K, Suzuki NN, Horiuchi M, Niki T, Taira T, Ariga H, Inagaki F. 2003b. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. *J Biol Chem* 278(33):31380-4.
- Hu CD, Chinenov Y, Kerppola TK. 2002. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. *Mol Cell* 9(4):789-98.
- Hu CD, Kerppola TK. 2003. Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis. *Nat Biotechnol* 21(5):539-45.
- Huai Q, Sun Y, Wang H, Chin LS, Li L, Robinson H, Ke H. 2003. Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. *FEBS Lett* 549(1-3):171-5.
- Huang N, Lee I, Marcotte EM, Hurles ME. 2010. Characterising and predicting haploinsufficiency in the human genome. *PLoS Genet* 6(10):e1001154.

- Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. *Brain* 125(Pt 4):861-70.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 55(3):181-4.
- Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M and others. 2008. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. *Lancet Neurol* 7(7):591-4.
- Hulleman JD, Mirzaei H, Guigard E, Taylor KL, Ray SS, Kay CM, Regnier FE, Rochet JC. 2007. Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease. *Biochemistry* 46(19):5776-89.
- Hurelbrink CB, Lewis SJ. 2011. Pathological considerations in the treatment of Parkinson's disease: more than just a wiring diagram. *Clin Neurol Neurosurg* 113(1):1-6.
- Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A and others. 1998. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 393(6686):702-5.
- Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. 2004. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. *Lancet* 364(9440):1169-71.
- Ibanez P, De Michele G, Bonifati V, Lohmann E, Thobois S, Pollak P, Agid Y, Heutink P, Durr A, Brice A. 2003. Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism. *Neurology* 61(10):1429-31.
- Ibanez P, Lesage S, Janin S, Lohmann E, Durif F, Destee A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D and others. 2009. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. *Arch Neurol* 66(1):102-8.
- Ibanez P, Lesage S, Lohmann E, Thobois S, De Michele G, Borg M, Agid Y, Durr A, Brice A. 2006. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. *Brain* 129(Pt 3):686-94.
- Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. 2001b. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. *Cell* 105(7):891-902.
- Imai Y, Soda M, Takahashi R. 2000. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. *J Biol Chem* 275(46):35661-4.
- Ishihara-Paul L, Hulihan MM, Kachergus J, Upmanyu R, Warren L, Amouri R, Elango R, Prinjha RK, Soto A, Kefi M and others. 2008. PINK1 mutations and parkinsonism. *Neurology* 71(12):896-902.

- Jackson PK. 2001. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. *Genes Dev* 15(23):3053-8.
- Jain S. 2011. Multi-organ autonomic dysfunction in Parkinson disease. *Parkinsonism Relat Disord* 17(2):77-83.
- Jain S, Heutink P. 2010. From single genes to gene networks: high-throughput-high-content screening for neurological disease. *Neuron* 68(2):207-17.
- Jang H, Choi DE, Kim H, Cho EJ, Youn HD. 2007. Cabin1 represses MEF2 transcriptional activity by association with a methyltransferase, SUV39H1. *J Biol Chem* 282(15):11172-9.
- Jenner P. 2003. Oxidative stress in Parkinson's disease. *Ann Neurol* 53(Suppl 3):S26-36; discussion S36-8.
- Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. *Ann Neurol* 32 Suppl:S82-7.
- Jin J, Li GJ, Davis J, Zhu D, Wang Y, Pan C, Zhang J. 2007. Identification of novel proteins associated with both alpha-synuclein and DJ-1. *Mol Cell Proteomics* 6(5):845-59.
- Johnson ES. 2004. Protein modification by SUMO. *Annu Rev Biochem* 73:355-82.
- Johnson J, Hague SM, Hanson M, Gibson A, Wilson KE, Evans EW, Singleton AA, McInerney-Leo A, Nussbaum RL, Hernandez DG and others. 2004. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. *Neurology* 63(3):554-6.
- Johnson J, Paisan-Ruiz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL and others. 2007. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. *Neurodegener Dis* 4(5):386-91.
- Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wu J and others. 2010. Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron* 68(5):857-64.
- Jones JM, Datta P, Srinivasula SM, Ji W, Gupta S, Zhang Z, Davies E, Hajnoczky G, Saunders TL, Van Keuren ML and others. 2003. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. *Nature* 425(6959):721-7.
- Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. 2005. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. *Proc Natl Acad Sci U S A* 102(27):9691-6.
- Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, Wieggers K, Schwinger E, Pramstaller PP, Breakefield XO and others. 2002. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. *Ann Neurol* 51(5):621-5.

- Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker HP, Hunot S and others. 2010. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. *J Clin Invest* 120(8):2745-54.
- Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J, Factor SA, Yu CE, Montimurro JS, Keefe RG and others. 2007. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. *Ann Neurol* 61(1):47-54.
- Kehagia AA, Barker RA, Robbins TW. 2010. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. *Lancet Neurol* 9(12):1200-13.
- Kerppola TK. 2006. Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. *Nat Protoc* 1(3):1278-86.
- Kerscher O. 2007. SUMO junction-what's your function? New insights through SUMO-interacting motifs. *EMBO Rep* 8(6):550-5.
- Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M and others. 2005. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. *Brain*. 128(12):2786-96.
- Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P. 2002. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. *Ann Neurol* 52(6):849-53.
- Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B and others. 2005. DJ-1, a novel regulator of the tumor suppressor PTEN. *Cancer Cell* 7(3):263-73.
- Kinumi T, Kimata J, Taira T, Ariga H, Niki E. 2004. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. *Biochem. Biophys. Res. Commun.* 317(3):722-8.
- Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392(6676):605-8.
- Klein C, Djarmati A, Hedrich K, Schafer N, Scaglione C, Marchese R, Kock N, Schule B, Hiller A, Lohnau T and others. 2005. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. *Eur J Hum Genet* 13(9):1086-93.
- Klein C, Lohmann-Hedrich K. 2007. Impact of recent genetic findings in Parkinson's disease. *Curr Opin Neurol* 20(4):453-64.

- Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. 2007. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. *Lancet Neurol* 6(7):652-62.
- Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM. 2006. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. *J Biol Chem* 281(24):16193-6.
- Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL and others. 2005. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. *J Neurosci* 25(35):7968-78.
- Kotaja N, Karvonen U, Janne OA, Palvimo JJ. 2002. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. *Mol Cell Biol* 22(14):5222-34.
- Kranick SM, Duda JE. 2008. Olfactory dysfunction in Parkinson's disease. *Neurosignals* 16(1):35-40.
- Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat Genet* 18(2):106-8.
- Lang AE, Lozano AM. 1998. Parkinson's disease. First of two parts. *N Engl J Med* 339(15):1044-53.
- Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219(4587):979-80.
- Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G, Brice A, Smith RJ. 2008. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. *Am J Hum Genet* 82(4):822-33.
- Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK. 2003. Mutations in NR4A2 associated with familial Parkinson disease. *Nat Genet* 33(1):85-9.
- Lee SJ, Kim SJ, Kim IK, Ko J, Jeong CS, Kim GH, Park C, Kang SO, Suh PG, Lee HS and others. 2003. Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. *J Biol Chem* 278(45):44552-9.
- Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. *Lancet* 373(9680):2055-66.
- Lencz T, Lambert C, DeRosse P, Burdick KE, Morgan TV, Kane JM, Kucherlapati R, Malhotra AK. 2007. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. *Proc Natl Acad Sci U S A* 104(50):19942-7.
- Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T and others. 1998. The ubiquitin pathway in Parkinson's disease. *Nature* 395(6701):451-2.

- Lesage S, Brice A. 2009. Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Hum Mol Genet* 18(R1):R48-59.
- Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A. 2006. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. *N Engl J Med* 354(4):422-3.
- Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. 2008. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. *J Med Genet* 45(1):43-6.
- Lesage S, Magali P, Lohmann E, Lacomblez L, Teive H, Janin S, Cousin PY, Durr A, Brice A. 2007. Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism. *Hum Mutat* 28(1):27-32.
- LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS and others. 2011. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol* 10(4):309-19.
- Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ, Chen JD. 2000. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. *Mol Cell Biol* 20(5):1784-96.
- Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolis CL, Schoenberg DG. 1985. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. *Arch Neurol* 42(7):655-7.
- Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, Kitaguchi M, Sasaki S, Kawaguchi S, Miyajima H and others. 2005. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. *Neurology* 64(11):1955-7.
- Lincoln SJ, Maraganore DM, Lesnick TG, Bounds R, de Andrade M, Bower JH, Hardy JA, Farrer MJ. 2003. Parkin variants in North American Parkinson's disease: cases and controls. *Mov Disord*. 18(11):1306-11.
- Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M and others. 2007. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. *Neurology* 68(11):812-9.
- Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK. 2003. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. *Mov Disord* 18(5):467-86.
- Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT, Jr. 2002. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. *Cell* 111(2):209-18.

- Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglia G, Mash DC, Farrer MJ. 2004. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. *J Med Genet* 41(3):e22.
- Loewenbruck K, Storch A. 2011a. Stem cell-based therapies in Parkinson's disease: future hope or current treatment option? *J Neurol* 258(Suppl 2):S346-53.
- Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussole E, Horstink MW, Vidailhet M and others. 2003. How much phenotypic variation can be attributed to parkin genotype? *Ann Neurol* 54(2):176-85.
- Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Deneffe P, Wood NW and others. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. *N Engl J Med* 342(21):1560-7.
- Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, Bainbridge M, Dinh H, Jing C, Wheeler DA and others. 2010. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. *N Engl J Med* 362(13):1181-91.
- Macedo MG, Anar B, Bronner IF, Cannella M, Squitieri F, Bonifati V, Hoogeveen A, Heutink P, Rizzu P. 2003. The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. *Hum Mol Genet* 12(21):2807-16.
- Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, Uras A, Groen JL, Rizzu P, van Hilten JJ and others. 2009. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. *Mov Disord* 24(2):196-203.
- Manyam BV, Sanchez-Ramos JR. 1999. Traditional and complementary therapies in Parkinson's disease. *Adv Neurol* 80:565-74.
- Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. 1999. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. *Science* 286(5440):785-90.
- Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S and others. 2003. Familial aggregation of early- and late-onset Parkinson's disease. *Ann Neurol* 54(4):507-13.
- Marongiu R, Brancati F, Antonini A, Ialongo T, Ceccarini C, Scarciolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B and others. 2007. Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. *Hum Mutat* 28(1):98.
- Maroteaux L, Campanelli JT, Scheller RH. 1988. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. *J Neurosci* 8(8):2804-15.
- Martin S, Wilkinson KA, Nishimune A, Henley JM. 2007. Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. *Nat Rev Neurosci* 8(12):948-59.

- Martins LM, Morrison A, Klupsch K, Fedele V, Moiso N, Teismann P, Abuin A, Grau E, Geppert M, Livi GP and others. 2004. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. *Mol Cell Biol* 24(22):9848-62.
- Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS and others. 2005. Lrrk2 pathogenic substitutions in Parkinson's disease. *Neurogenetics* 6(4):171-7.
- Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Samaranch L, Pastor P, Cervantes S and others. 2011. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. *Mov Disord* 26(5):819-23.
- Maxmen A. 2011. Exome sequencing deciphers rare diseases. *Cell* 144(5):635-7.
- McInerney-Leo A, Gwinn-Hardy K, Nussbaum RL. 2004. Prevalence of Parkinson's disease in populations of African ancestry: a review. *J Natl Med Assoc* 96(7):974-9.
- McLellan RA, Oscarson M, Alexandrie AK, Seidegard J, Evans DA, Rannug A, Ingelman-Sundberg M. 1997. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. *Mol Pharmacol* 52(6):958-65.
- McNaught KS, Olanow CW. 2003. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. *Ann Neurol* 53(Suppl 3):S73-84; discussion S84-6.
- McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. *Nat Rev Neurosci* 2(8):589-94.
- McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M, Barac-Lauc L, Smolej-Narancic N, Janicijevic B, Polasek O, Tenesa A and others. 2008. Runs of homozygosity in European populations. *Am J Hum Genet* 83(3):359-72.
- Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V and others. 2011. Priorities in Parkinson's disease research. *Nat Rev Drug Discov* 10(5):377-93.
- Melchior F, Schergaut M, Pichler A. 2003. SUMO: ligases, isopeptidases and nuclear pores. *Trends Biochem Sci* 28(11):612-8.
- Mercuri NB, Bernardi G. 2005. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? *Trends Pharmacol Sci* 26(7):341-4.
- Meulener M, Whitworth AJ, Armstrong-Gold CE, Rizzu P, Heutink P, Wes PD, Pallanck LJ, Bonini NM. 2005a. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. *Curr Biol* 15(17):1572-7.
- Meulener MC, Graves CL, Sampathu DM, Armstrong-Gold CE, Bonini NM, Giasson BI. 2005b. DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. *J Neurochem* 93(6):1524-32.

- Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J and others. 2003. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. *J Biol Chem* 278(38):36588-95.
- Mitsumoto A, Nakagawa Y. 2001. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. *Free Radic Res* 35(6):885-93.
- Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y. 2001. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. *Free Radic Res* 35(3):301-10.
- Moller JC, Rissling I, Mylius V, Hoft C, Eggert KM, Oertel WH. 2008. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease. *Eur J Neurol* 15(7):743-5.
- Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, Suda K, Mizuno Y. 1998. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. *Neurology* 51(3):890-2.
- Murphy KC. 2002. Schizophrenia and velo-cardio-facial syndrome. *Lancet* 359(9304):426-30.
- Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H. 1997. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. *Biochem Biophys Res Commun* 231(2):509-13.
- Nalls MA, Guerreiro RJ, Simon-Sanchez J, Bras JT, Traynor BJ, Gibbs JR, Launer L, Hardy J, Singleton AB. 2009. Extended tracts of homozygosity identify novel candidate genes associated with late-onset Alzheimer's disease. *Neurogenetics* 10(3):183-90.
- Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simon-Sanchez J, Schulte C, Lesage S, Sveinbjornsdottir S and others. 2011. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet* 377(9766):641-9.
- Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R and others. 2009. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. *Brain* 132(Pt 7):1783-94.
- Nichols WC, Kissell DK, Pankratz N, Pauculo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF and others. 2009. Variation in GIGYF2 is not associated with Parkinson disease. *Neurology* 72(22):1886-92.
- Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM, Ariga H. 2003. DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. *Mol Cancer Res* 1(4):247-61.

- Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H and others. 2006. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. *Ann Neurol* 59(2):298-309.
- Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M. 2010. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. *J Biol Chem* 285(45):34885-98.
- Olanow CW, Stern MB, Sethi K. 2009. The scientific and clinical basis for the treatment of Parkinson disease (2009). *Neurology* 72(21 Suppl 4):S1-136.
- Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC and others. 2003. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. *Ann Neurol* 53(5):624-9.
- Olzmann JA, Brown K, Wilkinson KD, Rees HD, Huai Q, Ke H, Levey AI, Li L, Chin LS. 2004. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. *J Biol Chem* 279(9):8506-15.
- Olzmann JA, Chin LS. 2008. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. *Autophagy* 4(1):85-7.
- Olzmann JA, Li L, Chudaev MV, Chen J, Perez FA, Palmiter RD, Chin LS. 2007. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. *J Cell Biol* 178(6):1025-38.
- Ooe H, Iguchi-Ariga SM, Ariga H. 2006. Establishment of specific antibodies that recognize C106-oxidized DJ-1. *Neurosci Lett* 404(1-2):166-9.
- Opsahl JA, Hjørnevik LV, Bull VH, Fismen L, Froyset AK, Gromyko D, Solstad T, Fladmark KE. 2010. Increased interaction between DJ-1 and the Mi-2/ nucleosome remodelling and deacetylase complex during cellular stress. *Proteomics* 10(7):1494-504.
- Outeiro TF, Lindquist S. 2003. Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science* 302(5651):1772-5.
- Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM and others. 2006. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. *N Engl J Med* 354(4):424-5.
- Paisan-Ruiz C. 2009. LRRK2 gene variation and its contribution to Parkinson disease. *Hum Mutat* 30(8):1153-60.
- Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA. 2009. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. *Ann Neurol* 65(1):19-23.

- Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N and others. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44(4):595-600.
- Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB. 2008. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. *Hum Mutat* 29(4):485-90.
- Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T. 2002. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. *Am J Hum Genet* 71(1):124-35.
- Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T and others. 2009. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. *Hum Genet* 124(6):593-605.
- Papapetropoulos S, Adi N, Shehadeh L, Bishopric N, Singer C, Argyriou AA, Chroni E. 2008. Is the G2019S LRRK2 mutation common in all southern European populations? *J Clin Neurosci* 15(9):1027-30.
- Parisiadou L, Cai H. 2010. LRRK2 function on actin and microtubule dynamics in Parkinson disease. *Commun Integr Biol* 3(5):396-400.
- Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM and others. 2006. Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. *Nature* 441(7097):1157-61.
- Parkinson J. 2002. An essay on the shaking palsy. 1817. *J Neuropsychiatry Clin Neurosci* 14(2):223-36; discussion 222.
- Parrish JR, Gulyas KD, Finley RL, Jr. 2006. Yeast two-hybrid contributions to interactome mapping. *Curr Opin Biotechnol* 17(4):387-93.
- Patterson N, Price AL, Reich D. 2006. Population structure and eigenanalysis. *PLoS Genet* 2(12):e190.
- Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. 2010. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. *Brain* 133(11):3434-43.
- Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. 2011. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. *Neuroimage* 56(3):1463-8.
- Payami H, Zarepars S, James D, Nutt J. 2002. Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. *Arch Neurol* 59(5):848-50.

- Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. 1994. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. *Biochem J* 300 (Pt 1):271-6.
- Perez-Pastene C, Graumann R, Diaz-Grez F, Miranda M, Venegas P, Godoy OT, Layson L, Villagra R, Matamala JM, Herrera L and others. 2007. Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component. *Neurosci Lett* 418(2):181-5.
- Periquet M, Latouche M, Lohmann E, Rawal N, De Michele G, Ricard S, Teive H, Fraix V, Vidailhet M, Nicholl D and others. 2003. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. *Brain*. 126(6):1271-8.
- Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J and others. 2002. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. *Neuron* 36(6):1007-19.
- Pezzoli G, Zini M. 2010. Levodopa in Parkinson's disease: from the past to the future. *Expert Opin Pharmacother* 11(4):627-35.
- Piccini P, Brooks DJ. 2006. New developments of brain imaging for Parkinson's disease and related disorders. *Mov Disord* 21(12):2035-41.
- Piccini P, Whone A. 2004. Functional brain imaging in the differential diagnosis of Parkinson's disease. *Lancet Neurol* 3(5):284-90.
- Pietraszewska-Bogiel A, Gadella TW. 2011. FRET microscopy: from principle to routine technology in cell biology. *J Microsc* 241(2):111-8.
- Pike CJ, Nguyen TV, Ramsden M, Yao M, Murphy MP, Rosario ER. 2008. Androgen cell signaling pathways involved in neuroprotective actions. *Horm Behav* 53(5):693-705.
- Plun-Favreau H, Klupsch K, Moiso N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N and others. 2007. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. *Nat Cell Biol* 9(11):1243-52.
- Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA and others. 1996. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science* 274(5290):1197-9.
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R and others. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276(5321):2045-7.
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. 2006. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 38(8):904-9.

- Pridgeon JW, Olzmann JA, Chin LS, Li L. 2007. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. *PLoS Biol* 5(7):e172.
- Quinn N, Critchley P, Marsden CD. 1987. Young onset Parkinson's disease. *Mov Disord* 2(2):73-91.
- Rabbee N, Speed TP. 2006. A genotype calling algorithm for affymetrix SNP arrays. *Bioinformatics* 22(1):7-12.
- Ragland M, Hutter C, Zabetian C, Edwards K. 2009. Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. *Am J Epidemiol* 170(11):1344-57.
- Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J and others. 2006. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. *Nat Genet* 38(10):1184-91.
- Ramsey CP, Giasson BI. 2010. L10p and P158DEL DJ-1 mutations cause protein instability, aggregation, and dimerization impairments. *J Neurosci Res* 88(14):3111-24.
- Rascol O, Lozano A, Stern M, Poewe W. 2011. Milestones in Parkinson's disease therapeutics. *Mov Disord* 26(6):1072-82.
- Rizzu P. 2003. DJ-1 colocalizes with pathological tau inclusions: A possible link between Parkinsonism and dementia. *Annals of Neurology* in press.
- Rizzu P, Hinkle DA, Zhukareva V, Bonifati V, Severijnen LA, Martinez D, Ravid R, Kamphorst W, Eberwine JH, Lee VM and others. 2004. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. *Ann Neurol* 55(1):113-8.
- Rizzu P, Joosse M, Ravid R, Hoogeveen A, Kamphorst W, van Swieten JC, Willemsen R, Heutink P. 2000. Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. *Hum Mol Genet* 9(20):3075-82.
- Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A and others. 2011. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurol* 10(10):898-908.
- Roy S, Wolman L. 1969. Ultrastructural observations in Parkinsonism. *J Pathol* 99(1):39-44.
- Rupniak MN, Jenner P, Marsden CD. 1983. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. *Life Sci* 32(20):2289-311.
- Rusnak F, Mertz P. 2000. Calcineurin: form and function. *Physiol Rev* 80(4):1483-521.

- Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, Vidailhet M, Mellick GD, Lohmann E, Durif F and others. 2011. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. *Hum Mol Genet* 20(3):615-27.
- Sahin E, Depinho RA. 2010. Linking functional decline of telomeres, mitochondria and stem cells during ageing. *Nature* 464(7288):520-8.
- Saito Y, Hamakubo T, Yoshida Y, Ogawa Y, Hara Y, Fujimura H, Imai Y, Iwanari H, Mochizuki Y, Shichiri M and others. 2009. Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. *Neurosci Lett* 465(1):1-5.
- Salinas AE, Wong MG. 1999. Glutathione S-transferases--a review. *Curr Med Chem* 6(4):279-309.
- Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, Pastor MA, Marrero C, Isla C, Herrera-Henriquez J and others. 2010. PINK1-linked parkinsonism is associated with Lewy body pathology. *Brain* 133(Pt 4):1128-42.
- Sarge KD, Park-Sarge OK. 2009. Sumoylation and human disease pathogenesis. *Trends Biochem Sci* 34(4):200-5.
- Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A and others. 2009. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. *Nat Genet* 41(12):1303-7.
- Savica R, Rocca WA, Ahlskog JE. 2010. When does Parkinson disease start? *Arch Neurol* 67(7):798-801.
- Schapira AH. 2010. Future strategies for neuroprotection in Parkinson's disease. *Neurodegener Dis* 7(1-3):210-2.
- Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengeler B, Hirsch E, Jenner P, Le Novere N and others. 2006. Novel pharmacological targets for the treatment of Parkinson's disease. *Nat Rev Drug Discov* 5(10):845-54.
- Scherer SW, Lee C, Birney E, Altshuler DM, Eichler EE, Carter NP, Hurles ME, Feuk L. 2007. Challenges and standards in integrating surveys of structural variation. *Nat Genet* 39(7 Suppl):S7-15.
- Scherfner C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W. 2007. Role of DAT-SPECT in the diagnostic work up of parkinsonism. *Mov Disord* 22(9):1229-38.
- Scherzer CR, Jensen RV, Gullans SR, Feany MB. 2003. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. *Hum Mol Genet* 12(19):2457-66.

- Scholz SW. 2009. PINK1 mutations: does the dosage make the poison? *Hum Mutat* 30(11):v.
- Seidel K, Schols L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, Dickson D, Gai WP, Bornemann A, Riess O and others. 2010. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. *Ann Neurol* 67(5):684-9.
- Shalizi A, Gaudilliere B, Yuan Z, Stegmuller J, Shirogane T, Ge Q, Tan Y, Schulman B, Harper JW, Bonni A. 2006. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. *Science* 311(5763):1012-7.
- Sharma M, Mueller JC, Zimprich A, Lichtner P, Hofer A, Leitner P, Maass S, Berg D, Durr A, Bonifati V and others. 2006. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. *J Med Genet* 43(7):557-62.
- Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. 2004. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. *PLoS Biol* 2(11):e362.
- Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. 2003. Mechanism of toxicity in rotenone models of Parkinson's disease. *J Neurosci* 23(34):10756-64.
- Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D and others. 2010. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. *Neurosci Lett* 480(1):78-82.
- Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K and others. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet* 25(3):302-5.
- Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. 2001. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. *Science* 293(5528):263-9.
- Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, Maita C, Seino C, Iguchi-Arigo SM, Ariga H. 2006. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. *Cell Death Differ* 13(1):96-108.
- Shinbo Y, Taira T, Niki T, Iguchi-Arigo SM, Ariga H. 2005. DJ-1 restores p53 transcription activity inhibited by Topors/p53BP3. *Int J Oncol* 26(3):641-8.
- Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, Popat R, Leimpeter A, Bernstein AL, Nelson LM. 2010. Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. *Mov Disord* 25(15):2587-94.

- Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A and others. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N Engl J Med* 361(17):1651-61.
- Simon-Sanchez J, Scholz S, Fung HC, Matarin M, Hernandez D, Gibbs JR, Britton A, de Vrieze FW, Peckham E, Gwinn-Hardy K and others. 2007. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. *Hum Mol Genet* 16(1):1-14.
- Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG and others. 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat Genet* 41(12):1308-12.
- Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW, Arepalli S, Hernandez DG, de Bie RM, Velseboer D, Scheffer H and others. 2011. Genome-wide association study confirms extant PD risk loci among the Dutch. *Eur J Hum Genet* 19(6):655-61.
- Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. 2008. Polymorphism in environment responsive genes and association with Parkinson disease. *Mol Cell Biochem* 312(1-2):131-8.
- Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R and others. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 302(5646):841.
- Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, Barker RA, Bellenguez C, Bhatia K, Blackburn H and others. 2011. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. *Hum Mol Genet* 20(2):345-53.
- Spillantini MG, Divane A, Goedert M. 1995. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. *Genomics* 27(2):379-81.
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. *Nature* 388(6645):839-40.
- Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Muller T, Bornemann A and others. 2005. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. *Hum Mol Genet* 14(15):2099-111.
- Stroombergen MC, Waring RH. 1999. Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. *Hum Exp Toxicol* 18(3):141-5.
- Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L, van Driel R. 1992. A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. *J Cell Sci* 101 (Pt 4):773-84.

- Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S and others. 2010. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. *Dis Model Mech* 3(3-4):194-208.
- Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG. 2009. Mitochondrial accumulation of polyubiquitinated proteins and differential regulation of apoptosis by polyubiquitination sites Lys-48 and -63. *J Cell Mol Med* 13(8B):1632-43.
- Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. 2001. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. *Mol Cell* 8(3):613-21.
- Syken J, Shatz CJ. 2003. Expression of T cell receptor beta locus in central nervous system neurons. *Proc Natl Acad Sci U S A* 100(22):13048-53.
- Taira T, Saito Y, Niki T, Iguchi-Arigo SM, Takahashi K, Ariga H. 2004. DJ-1 has a role in antioxidative stress to prevent cell death. *EMBO Rep.* 5(2):213-8.
- Taira T, Takahashi K, Kitagawa R, Iguchi-Arigo SM, Ariga H. 2001. Molecular cloning of human and mouse DJ-1 genes and identification of Sp1-dependent activation of the human DJ-1 promoter. *Gene* 263(1-2):285-92.
- Takahashi-Niki K, Niki T, Taira T, Iguchi-Arigo SM, Ariga H. 2004. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. *Biochem. Biophys. Res. Commun.* 320(2):389-97.
- Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, Tsuji S, Ikuta F. 1994. Familial juvenile parkinsonism: clinical and pathologic study in a family. *Neurology* 44(3 Pt 1):437-41.
- Takahashi K, Taira T, Niki T, Seino C, Iguchi-Arigo SM, Ariga H. 2001. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. *J Biol Chem* 276(40):37556-63.
- Tan EK, Refai FS, Siddique M, Yap K, Ho P, Fook-Chong S, Zhao Y. 2009. Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. *Hum Mutat* 30(11):1551-7.
- Tan EK, Skipper LM. 2007. Pathogenic mutations in Parkinson disease. *Hum Mutat* 28(7):641-53.
- Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH and others. 2006. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. *Hum Mol Genet* 15(11):1816-25.
- Tao X, Tong L. 2003. Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. *J Biol Chem* 278(33):31372-9.

- Terreni L, Calabrese E, Calella AM, Forloni G, Mariani C. 2001. New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. *Neurology* 56(4):463-6.
- Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S. 2007. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. *Cancer Res* 67(10):4630-7.
- Toft M, Dietrichs E. 2011. Aggravated stuttering following subthalamic deep brain stimulation in Parkinson's disease--two cases. *BMC Neurol* 11:44.
- Touchman JW, Dehejia A, Chiba-Falek O, Cabin DE, Schwartz JR, Orrison BM, Polymeropoulos MH, Nussbaum RL. 2001. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. *Genome Res* 11(1):78-86.
- Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM. 1998. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. *Cell Death Differ* 5(10):832-7.
- Troster AI. 2011. Parkinson disease: Deep brain stimulation and neuropsychology: a step forward? *Nat Rev Neurol*.
- Trotter EW, Kao CM, Berenfeld L, Botstein D, Petsko GA, Gray JV. 2002. Misfolded proteins are competent to mediate a subset of the responses to heat shock in *Saccharomyces cerevisiae*. *J Biol Chem* 277(47):44817-25.
- Um JW, Chung KC. 2006. Functional modulation of parkin through physical interaction with SUMO-1. *J Neurosci Res* 84(7):1543-54.
- Urduingio RG, Sanchez-Mut JV, Esteller M. 2009. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. *Lancet Neurol* 8(11):1056-72.
- Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG and others. 2004a. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* 304(5674):1158-60.
- Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR. 2004b. PINK1 mutations are associated with sporadic early-onset parkinsonism. *Ann Neurol* 56(3):336-41.
- van der Brug MP, Blackinton J, Chandran J, Hao LY, Lal A, Mazan-Mamczarz K, Martindale J, Xie C, Ahmad R, Thomas KJ and others. 2008. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. *Proc Natl Acad Sci U S A* 105(29):10244-9.
- Vasseur S, Afzal S, Tardivel-Lacombe J, Park DS, Iovanna JL, Mak TW. 2009. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. *Proc Natl Acad Sci U S A* 106(4):1111-6.

- Venegas-Francke P. 2010. Transcranial sonography in the discrimination of Parkinson's disease versus vascular parkinsonism. *Int Rev Neurobiol* 90:147-56.
- Verbaan D, Boesveldt S, van Rooden SM, Visser M, Marinus J, Macedo MG, Fang Y, Heutink P, Berendse HW, van Hilten JJ. 2008a. Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics? *Neurology* 71(23):1877-82.
- Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. 2007. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. *Mov Disord*.
- Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. 2008b. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. *Mov Disord*.
- Videnovic A, Metman LV. 2008. Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting. *Mov Disord* 23(3):343-9.
- Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ. 2007. Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC. *Mov Disord* 22(15):2221-8.
- Wagenfeld A, Gromoll J, Cooper TG. 1998. Molecular cloning and expression of rat contraception associated protein 1 (CAP1), a protein putatively involved in fertilization. *Biochem Biophys Res Commun* 251(2):545-9.
- Wakeman DR, Dodiya HB, Kordower JH. 2011. Cell transplantation and gene therapy in Parkinson's disease. *Mt Sinai J Med* 78(1):126-58.
- Wang Y. 1991. [The incidence and prevalence of Parkinson's disease in the People's Republic of China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 12(6):363-5.
- Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M. 2010. alpha-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson's Disease. *Int J Mol Sci* 11(11):4257-66.
- Ward CL, Kopito RR. 1994. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. *J Biol Chem* 269(41):25710-8.
- Waters PJ. 2001. Degradation of mutant proteins, underlying "loss of function" phenotypes, plays a major role in genetic disease. *Curr Issues Mol Biol* 3(3):57-65.
- Webber PJ, West AB. 2009. LRRK2 in Parkinson's disease: function in cells and neurodegeneration. *Febs J* 276(22):6436-44.
- Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. *Biochemistry* 35(43):13709-15.
- Weintraub D, Burn DJ. 2011. Parkinson's disease: the quintessential neuropsychiatric disorder. *Mov Disord* 26(6):1022-31.

- Wenning GK, Litvan I, Tolosa E. 2011. Milestones in atypical and secondary Parkinsonisms. *Mov Disord* 26(6):1083-95.
- West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc Natl Acad Sci U S A*. 102(46):16842-7.
- White DL, Li D, Nurgalieva Z, El-Serag HB. 2007. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. *Am J Epidemiol* 167(4):377-89.
- Wiley J, Lynch T, Lincoln S, Skipper L, Hulihan M, Gosal D, Bisceglia G, Kachergus J, Hardy J, Farrer MJ. 2004. Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations. *Mov Disord* 19(6):677-81.
- Wilkinson KA, Henley JM. 2010. Mechanisms, regulation and consequences of protein SUMOylation. *Biochem J* 428(2):133-45.
- Wilkinson KA, Nakamura Y, Henley JM. 2010. Targets and consequences of protein SUMOylation in neurons. *Brain Res Rev* 64(1):195-212.
- Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA. 2006. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. *J Neurol Neurosurg Psychiatry* 77(5):665-7.
- Williams NM, O'Donovan MC, Owen MJ. 2006. Chromosome 22 deletion syndrome and schizophrenia. *Int Rev Neurobiol* 73:1-27.
- Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. 2003. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. *Science* 302(5651):1769-72.
- Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA. 2003. The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. *Proc. Natl. Acad. Sci. USA* 100(16):9256-61.
- Winter Y, Balzer-Geldsetzer M, Spottke A, Reese JP, Baum E, Klotsche J, Rieke J, Simonow A, Eggert K, Oertel WH and others. 2010. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. *Eur J Neurol* 17(9):1156-63.
- Wood LD, Neumiller JJ, Setter SM, Dobbins EK. 2010. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. *Am J Geriatr Pharmacother* 8(4):294-315.
- Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. 1997. Characterization of the CHD family of proteins. *Proc Natl Acad Sci U S A* 94(21):11472-7.

- Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. 1994. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. *Proc Natl Acad Sci U S A* 91(19):9014-8.
- Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X and others. 2009. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. *J Clin Invest* 119(3):650-60.
- Xiomerisiou G, Dardiotis E, Tsimourto V, Kountra PM, Paterakis KN, Kapsalaki EZ, Fountas KN, Hadjigeorgiou GM. 2010. Genetic basis of Parkinson disease. *Neurosurg Focus* 28(1):E7.
- Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. *Nat Med* 8(6):600-6.
- Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA. 2005. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. *Hum Mol Genet* 14(9):1231-41.
- Xue Y, Wong J, Moreno GT, Young MK, Cote J, Wang W. 1998. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. *Mol Cell* 2(6):851-61.
- Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR and others. 2009. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. *Nat Genet* 41(3):316-23.
- Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B and others. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol* 55(2):164-73.
- Zhang F, Gu W, Hurler ME, Lupski JR. 2009. Copy number variation in human health, disease, and evolution. *Annu Rev Genomics Hum Genet* 10:451-81.
- Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI, Torp R, Torgner IA, Ottersen OP, Dawson TM and others. 2005. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. *Hum Mol Genet* 14(14):2063-73.
- Zhang Y. 2010. Biology of the Mi-2/NuRD Complex in SLAC (Stemness, Longevity/Ageing, and Cancer). *Gene Regul Syst Bio* 5:1-26.
- Zhang Y, Dawson VL, Dawson TM. 2000a. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. *Neurobiol Dis* 7(4):240-50.

- Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. 2000b. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. *Proc Natl Acad Sci U S A* 97(24):13354-9.
- Zhong N, Kim C'Y, Rizzu P, Geula C, Porter DR, Pothen EN, Squitieri F, Heutink P, Xu J. 2006. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of PSF. *J Biol Chem*.
- Zhong N, Xu J. 2008. Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation. *Hum Mol Genet* 17(21):3357-67.
- Zhou C, Huang Y, Shao Y, May J, Prou D, Perier C, Dauer W, Schon EA, Przedborski S. 2008. The kinase domain of mitochondrial PINK1 faces the cytoplasm. *Proc Natl Acad Sci U S A* 105(33):12022-7.
- Zhou W, Freed CR. 2005. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. *J Biol Chem* 280(52):43150-8.
- Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB and others. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 44(4):601-7.
- Zucchelli S, Codrich M, Marcuzzi F, Pinto M, Vilotti S, Biagioli M, Ferrer I, Gustincich S. 2010. TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains. *Hum Mol Genet* 19(19):3759-70.